Insights

In a non-precedential decision, the Federal Circuit affirmed a decision of the Patent Trial and Appeal Board (PTAB or Board) that certain claims of Qualcomm’s U.S. Patent No. 8,838,949 (titled “Direct Scatter Loading of Executable Software Im… Read More

The Ninth Circuit has affirmed a ruling that the advertisement and sale of equity in a company cannot constitute trademark infringement. The case is LegalForce RAPC Worldwide, P.C. v. LegalForce Inc. LegalForce RAPC Worldwide, P.C. (“LegalForce USA… Read More

Your intellectual property (IP) may be your business’s most important asset, especially if you’re operating in the technology space. According to Forbes, non-tangible assets are over 80% of the average business’ value. When it comes to startups… Read More

Artificial Intelligence (AI) in general, and generative AI (GAI) – such as ChatGPT- in particular, continue to be very much in the news. As Reuters reported, on January 21, President Donald Trump announced “a private sector investment of up to $5… Read More

The Federal Circuit has affirmed a district court judgment finding that Purdue Pharma’s patent claims to crush-resistant and low-toxicity OxyContin were invalid as obvious. The case involves patents related to Purdue’s formulation of extended-rel… Read More

Patents are a form of intellectual property – an asset. However, the value of that asset can be uncertain. As the European Patent Office (EPO) explains, Methods of evaluating patents for business purposes can be divided into quantitative and qualit… Read More

The Federal Circuit has vacated and remanded a decision by the Patent Trial and Appeal Board (PTAB or Board), finding that Palo Alto Networks failed to establish that certain claims of Centripetal Networks patents were unpatentable as obvious. The co… Read More

The Federal Circuit recently issued two precedential decisions in patent cases. In Galderma Laboratories v. Lupin, the court affirmed a district court’s decision that Lupin’s abbreviated new drug application (ANDA) did not infringe Galderma’s t… Read More